Life Sciences Times

AstraZeneca Completes Global Licensing Deal for Lung Cancer Drug ZEGFROVY

Greater Boston Urology Adds Dr. Akash Sharma and Dr. Rafael Tua-Caraccia

Stoke Therapeutics, Biogen Report Long-Term Zorevunersen Data in Dravet Syndrome

Guardant Health’s Shield Blood Test Gains Carelon Coverage for Colorectal Cancer Screening

Vertex Completes $10 Billion Acquisition of Crinetics, Expands Leadership Team

Ascletis Doses First Participant in Global Phase 3 Program for Oral GLP-1 Drug ASC30

Amgen Reports Repatha Reduced Risk of Death in High-Risk Patients Without Prior Heart Attack or Stroke

Lilly Reports One-Year Phase 3b Data for Taltz and Zepbound in Psoriatic Disease and Obesity

NeuroSense Outlines Accelerated Development Strategy for PrimeC in ALS

Lilly to Acquire Merida Biosciences in Deal Worth Up to $2.875 Billion